#TCR-directed
@biorxivpreprint.bsky.social CD8 Tregs may derive from the same TCR-directed developmental program that generates natural IELs
www.biorxiv.org/content/10.6...
November 14, 2026 at 5:16 PM
Our findings suggest that CD8 Tregs may derive from the same #TCR-directed developmental program that generates natural IELs and shed light on the origins of these immunoregulatory cells.
November 14, 2026 at 1:18 PM
AI agent swarms complete a computer-checked proof of the enormous theorem

Sources:
https://axiommath.ai/research/the-enormous-theorem-formalized/

See other stories with deeper dives at https://sharedsapience.com/century-report/?utm_source=bluesky&utm_medium=post&utm_campaign=tcr-newsroom
October 31, 2026 at 3:41 PM
Historical background that led to the Nobel Prize 2025 by Nobel Laureate Richard Robson in the Chemical Record doi.org/10.1002/tcr....
The Historical Development of the Concepts Underlying the Design and Construction of Targeted Coordination Polymers/MOFs: A Personal Account
A pre-organized metallo-porphyrin substituted by four 4-pyridyl donors directed outwards towards the corners of a square, seen here providing the square planar node in a coordination polymer framewor...
doi.org
October 8, 2025 at 10:17 AM
arXiv📈🤖
Identifying expanding TCR clonotypes with a longitudinal Bayesian mixture model and their associations with cancer patient prognosis, metastasis-directed therapy, and VJ gene enrichment
By Swanson, Sherry, Haymaker et al
January 9, 2026 at 4:30 PM
I think in an antigen-receptor centric world(view), cytokines are underappreciated.

www.science.org/doi/10.1126/...
Induction of Bystander T Cell Proliferation by Viruses and Type I Interferon in Vivo
T cell proliferation in vivo is presumed to reflect a T cell receptor (TCR)-mediated polyclonal response directed to various environmental antigens. However, the massive proliferation of T cells seen ...
www.science.org
November 19, 2024 at 5:02 PM
Online now: Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation
Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation
Sagie et al. identify a KRAS.G12V-specific TCR and show that lymphodepleting chemotherapy enhances antigen presentation via immunoproteasome activation and HLA-I upregulation. Together, these changes synergize to improve T cell-mediated tumor killing in multiple models and highlight the potential of optimized chemotherapy to augment adoptive cell therapy efficacy.
dlvr.it
December 18, 2025 at 1:27 PM
The Women of African Methodism anthology series is an intergenerational documentary to harness the power of the voices of women upholding the legacy of our traditions and ushering a refreshing of our faith. #WomenofAfricanMethodism #AMEC #AfricanMethodistEpiscopalChurch
Announcing the Women of African Methodism Anthology!
Proceeds will be directed to the stewardship of the AME Publications Commission.  This project is spearheaded by TCR columnist Dora Muhammad...
thenetbible.blogspot.com
December 15, 2025 at 10:19 PM
Wermke et al. reported interim data from a phase 1 dose-escalation trial of IMA203 – PRAME-directed autologous TCR T cell therapy – in HLA-A*02+ patients with PRAME+ recurrent and/or refractory solid tumors. bit.ly/4jqlIK9  
April 25, 2025 at 4:00 PM
Cool burst of research, I think a lot of cancers will eventually get downgraded to inconveniences through pMHC directed therapies (or compensatory NK therapies to clean up MHC null escape)

www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
De novo design and structure of a peptide–centric TCR mimic binding module
T cell receptor (TCR) mimics offer a promising platform for tumor-specific targeting of peptide–major histocompatibility complex (pMHC) in cancer immunotherapy. In this study, we designed a de novo α-...
www.science.org
July 24, 2025 at 7:57 PM
Promising results from Ph 1 trial of autologous PRAME-directed TCR-T cell therapy in HLA-A*02+ patients with PRAME+ recurrent and/or refractory solid tumors.

Out now in @naturemedicine.bsky.social!

Enrolment for Ph 3 trial of IMA203 ongoing 👇
clinicaltrials.gov/study/NCT067...
April 9, 2025 at 5:51 PM
Identification of clonally expanded T-cell receptor sequences in giant cell arteritis
Identification of clonally expanded T-cell receptor sequences in giant cell arteritis - PubMed
Our data provide evidence of circulating T-cell clonal expansions in GCA patients. Certain TCR sequence patterns were over-represented in GCA subjects. As more TCR sequences directed at human antigens...
pubmed.ncbi.nlm.nih.gov
February 9, 2025 at 2:35 AM
TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer https://pubmed.ncbi.nlm.nih.gov/39172012/
September 6, 2024 at 10:01 AM
Parts 1-4/4 — EFTA01254094.jpg
#epsteinweb #efta01254094
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
May 14, 2026 at 8:52 AM
Parts 1-4/4 — EFTA01291790.jpg
#epsteinweb #efta01291790
https://epsteinweb.org
February 16, 2026 at 3:25 PM
Parts 1-3/3 — EFTA01289990.jpg
#epsteinweb #efta01289990
https://epsteinweb.org
February 16, 2026 at 1:50 PM
Parts 1-4/4 — EFTA01288487.jpg
#epsteinweb #efta01288487
https://epsteinweb.org
February 16, 2026 at 12:33 PM
Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells
a CD8+ T cells isolated from peripheral blood mononuclear cells of four healthy donors were stimulated with anti-CD3/CD28 beads, IL-2 and IL-7, and transfected with TRAC- and TRBC-targeting ribonucleoprotein complexes to assess endogenous TCR knockout efficiency (left). Subsequently, the transfections were repeated in seven healthy donors with a double-stranded DNA homology-directed repair template, enabling insertion of the PDL101-TCR into the TRAC locus. Engineered T cells were purified as CD3+PDL101-tetramer+ cells using fluorescence-activated cell sorting and expanded with the rapid expansion protocol. Antigen specificity before and after enrichment was assessed by staining with control- (HLTV-1 Tax11-19) or PDL101 peptide-loaded HLA-A2 tetramers (middle). Antigen-dependent upregulation of IFN-γ, TNF-α and CD107a was quantified using intracellular cytokine staining (ICS) following PDL101 peptide stimulation (5 µM, right). Each data point represents a separate donor and shows the fraction of PDL101-tetramer+ cells, IFN-γ+/TNF-α+ cells or CD107a+ cells within the CD8+ population. b Antigen-specific cytotoxicity was assessed by 51Cr-release assays using radioactively labeled T2 cells loaded with either DMSO, PDL101 or PDL1Long1 (4 h, 20 µM) as target cells for enriched PDL101-TCR-T cells from five donors (left). Thin lines represent mean target cell lysis of technical duplicate or triplicate measurements for individual donors, whereas the thick lines...
www.nature.com
June 24, 2026 at 2:28 AM
#ICYMI: At #ESMOImmuno25, Antonia Busse presented, “A phase I trial of IMA203CD8, a PRAME-directed TCR T cell therapy in PRAME-positive solid tumors”.
December 11, 2025 at 1:00 PM
I'm really pleased that our collaboration with Shira Sagie, Tomer Babu and Yardena Samuels has been published in Cell Reports Medicine. This has been a really fun and productive collaboration as well as an incredible learning process.
www.cell.com/cell-reports...
Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation
Sagie et al. identify a KRAS.G12V-specific TCR and show that lymphodepleting chemotherapy enhances antigen presentation via immunoproteasome activation and HLA-I upregulation. Together, these changes ...
www.cell.com
December 17, 2025 at 11:49 AM